Grace Therapeutics, Inc. (GRCE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00439U1043
Grace Therapeutics, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Operating income | -16.68 m USD | -11.08 m USD |
| EBIT | -13.48 m USD | -10.18 m USD |
| Net income | -9.57 m USD | -7.79 m USD |
| Diluted EPS – continuing operations | -0.79 USD | -0.47 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
More stocks
- Derkwoo Electronics Co., Ltd (263600.KQ)
- Aptera Motors Corp (SEV)
- SCI Engineered Materials, Inc. (SCIA)
- YIHO International Co., Ltd. (7590.TWO)
- Mountain Crest Acquisition Corp. V (MCAG)
- Xtant Medical Holdings, Inc. (XTNT)
- Streamex Corp. (STEX)
- Sensus Healthcare, Inc. (SRTS)
- Cellid Co. Ltd (299660.KQ)
- ACORN ENERGY, INC. (ACFN)
- Aquabb (AQU.WA)
- NOMAD POWER SOLUTIONS, INC. (NMAD)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.